Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA
Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review
The observation that dendritic cells (DCs) charged with tumor-associated antigens (TAAs) is a potent strategy to elicit protective immunity in tumor-bearings hosts has prompted extensive testing of DCs as cellular adjuvant in cancer vaccines. To improve the clinical development of DC-based cancer vaccines, it may be beneficial to analyze preexistent immunity against TAAs in cancer patients because it may be easier to expand a memory pool of T cells compared to generating new immunity. Recent research shows that engineering DCs to synthesize tumor epitopes endogenously by transfecting DCs with mRNA-encoding TAAs are particular effective in stimulating robust T-responses in vitro and in vivo. In this chapter, we describe the methodology to analyze for survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.
Original language | English |
---|---|
Title of host publication | Synthetic Messenger RNA and Cell Metabolism Modulation |
Number of pages | 18 |
Volume | 969 |
Publication date | 2013 |
Pages | 275-292 |
ISBN (Print) | 978-1-62703-259-9 |
DOIs | |
Publication status | Published - 2013 |
Series | Methods in Molecular Biology |
---|---|
ISSN | 1064-3745 |
ID: 245670540